Clinical Outcomes, Treatment Patterns, and Molecular Heterogeneity of TFE3 ‐Rearranged Renal Cell Carcinoma: A Multicenter Real‐World Study
Cancer Medicine · 2026
DOI: 10.1002/cam4.72268 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2026. Verfasst von Shuxuan Zhu und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, Kidney Neoplasms, Gene Rearrangement. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Scientific Innovation Project of Shanghai Education Committee, Beijing Xisike Clinical Oncology Research Foundation, Shanghai Anti-Cancer Association Eyas Project.
Abstract (Originalsprache)
Background
TFE3‐rearranged renal cell carcinoma (TFE3‐rRCC) is uncommon and encompasses biologically diverse tumors, while evidence to guide systemic treatment remains sparse. We examined clinical outcomes, treatment patterns, and molecular features in a multicenter real‐world cohort.
Methods
We reviewed 151 patients with TFE3‐rRCC treated at eight centers in China. Treatment analyses included the 59 patients who had metastatic or relapsed disease and sufficiently detailed treatment records. Response was assessed by RECIST version 1.1. Kaplan–Meier methods were used for time‐to‐event outcomes, and potential confounding was explored with Cox regression.
Results
Median first‐line progression‐free survival (PFS) was 6.1 months among the 59 treated patients. PFS was longer with first‐line ICI/TKI therapy than with TKI monotherapy (log‐rank p = 0.034). In an exploratory multivariable model, distant lymph‐node metastasis was associated with shorter overall survival (HR, 5.22; 95% CI, 1.17–23.40; p = 0.031). In a small subgroup comparison, NONO‐TFE3 tumors had a relatively immune‐depleted transcriptomic profile and lower disease control with ICI/TKI therapy.
Conclusions
TFE3 ‐rRCC is a heterogeneous disease with poor survival and a variable therapeutic response. ICI/TKI combinations had modest activity; newer approaches are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
- Shanghai Genitourinary Cancer Institute, Shanghai, People's Republic of China.
- Department of Urology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.
- Department of Urology, Daping Hospital, Army Medical University, Chongqing, People's Republic of China.
- Department of Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
ORCID-Profile: Shuxuan Zhu, Xi Tian, Jun Jiang, Qiuli Liu, Xin Gou, Jianfeng Yang, Aihetaimujiang Anwaier, Yuanyuan Qu, Wenhao Xu, Dingwei Ye
Förderung
- Scientific Innovation Project of Shanghai Education Committee
- Beijing Xisike Clinical Oncology Research Foundation
- Shanghai Anti-Cancer Association Eyas Project
- Shanghai Municipal Health Bureau
- National Natural Science Foundation of China
Zitieren
APA
Zhu, S., Zhou, S., Tian, X., Wang, J., Wang, Z., Jiang, J., Liu, Q., Gou, X., Zhou, X., Gu, J., Yang, J., Chen, J., Chen, S., Wang, W., Anwaier, A., Chang, K., Qu, Y., Brugarolas, J., Xu, W., …, & Ye, D. (2026). Clinical Outcomes, Treatment Patterns, and Molecular Heterogeneity of TFE3 ‐Rearranged Renal Cell Carcinoma: A Multicenter Real‐World Study. Cancer Medicine. https://doi.org/10.1002/cam4.72268
Vancouver
Zhu S, Zhou S, Tian X, Wang J, Wang Z, Jiang J, et al. Clinical Outcomes, Treatment Patterns, and Molecular Heterogeneity of TFE3 ‐Rearranged Renal Cell Carcinoma: A Multicenter Real‐World Study. Cancer Medicine. 2026. doi:10.1002/cam4.72268
BibTeX
@article{Zhu2026,
author = {Zhu, Shuxuan and Zhou, Siqi and Tian, Xi and Wang, Jun and Wang, Ze and Jiang, Jun and Liu, Qiuli and Gou, Xin and Zhou, Xiang and Gu, Jun and Yang, Jianfeng and Chen, Jianhui and Chen, Shushang and Wang, Wenfeng and Anwaier, Aihetaimujiang and Chang, Kun and Qu, Yuanyuan and Brugarolas, James and Xu, Wenhao and Zhang, Hailiang and Ye, Dingwei},
title = {Clinical Outcomes, Treatment Patterns, and Molecular Heterogeneity of TFE3 ‐Rearranged Renal Cell Carcinoma: A Multicenter Real‐World Study},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.72268}
}
EUVIMED